⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28673944 | 1.00 | — | — | |
| SCHEMBL4701726 | 0.86 | — | — | |
| SCHEMBL8259945 | 0.86 | — | — | |
| SCHEMBL29160901 | 0.84 | CCR2 (0.35) | — | |
| SCHEMBL23462764 | 0.76 | — | — | |
| SCHEMBL247639 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL16703074 | 0.72 | — | — | |
| SCHEMBL5506391 | 0.70 | — | — | |
| SCHEMBL3738807 | 0.70 | — | — | |
| SCHEMBL2081347 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220340523-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| CN-110511213-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-10-19 | — | — | CN | disclosed |
| WO-2021154997-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021108581-A1 | POTENT AND SELECTIVE AZAINDOLE INHIBITORS OF CDK8 AND CDK19 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021102204-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-110511213-A | A kind of immunomodulator | CHENGDU HITGEN DEV CO LTD | 2019-11-29 | — | — | CN | disclosed |
| US-4757068-A | Lactams and bicyclic lactams useful as cholecystokinin antagonists | MERCK & CO., INC. (US) | 1988-07-12 | — | — | US | disclosed |